Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Vitamin D supplementation has no effect on cognitive performance after four months in mid-aged and older subjects.

Jorde R, Kubiak J, Svartberg J, Fuskevåg OM, Figenschau Y, Martinaityte I, Grimnes G.

J Neurol Sci. 2019 Jan 15;396:165-171. doi: 10.1016/j.jns.2018.11.020. Epub 2018 Nov 17.

PMID:
30472553
2.

Cortisol levels and cognitive profile in major depression: A comparison of currently and previously depressed patients.

Høifødt RS, Waterloo K, Wang CEA, Eisemann M, Figenschau Y, Halvorsen M.

Psychoneuroendocrinology. 2019 Jan;99:57-65. doi: 10.1016/j.psyneuen.2018.08.024. Epub 2018 Aug 22.

PMID:
30176378
3.

Failure to Find a Conditioned Placebo Analgesic Response.

Flaten MA, Bjørkedal E, Lyby PS, Figenschau Y, Aslaksen PM.

Front Psychol. 2018 Jul 30;9:1198. doi: 10.3389/fpsyg.2018.01198. eCollection 2018.

4.

Co-expression of 1α-hydroxylase and vitamin D receptor in human articular chondrocytes.

Hansen AK, Figenschau Y, Zubiaurre-Martinez I.

BMC Musculoskelet Disord. 2017 Nov 6;18(1):432. doi: 10.1186/s12891-017-1791-y.

5.

The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.

Snapkov I, Öqvist CO, Figenschau Y, Kogner P, Johnsen JI, Sveinbjørnsson B.

BMC Cancer. 2016 Jul 18;16:490. doi: 10.1186/s12885-016-2545-1.

6.

Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes.

Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I, Fuskevåg OM, Figenschau Y, Hutchinson MY.

J Clin Endocrinol Metab. 2016 Apr;101(4):1647-55. doi: 10.1210/jc.2015-4013. Epub 2016 Feb 1.

PMID:
26829443
7.

Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D.

Sollid ST, Hutchinson MY, Berg V, Fuskevåg OM, Figenschau Y, Thorsby PM, Jorde R.

Eur J Endocrinol. 2016 Apr;174(4):445-52. doi: 10.1530/EJE-15-1089. Epub 2016 Jan 5.

8.

Human articular chondrocytes express functional leukotriene B4 receptors.

Hansen AK, Indrevik JT, Figenschau Y, Martinez-Zubiaurre I, Sveinbjörnsson B.

J Anat. 2015 Mar;226(3):268-77. doi: 10.1111/joa.12275. Epub 2015 Feb 9.

9.

No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes.

Sollid ST, Hutchinson MY, Fuskevåg OM, Figenschau Y, Joakimsen RM, Schirmer H, Njølstad I, Svartberg J, Kamycheva E, Jorde R.

Diabetes Care. 2014 Aug;37(8):2123-31. doi: 10.2337/dc14-0218. Epub 2014 Jun 19.

PMID:
24947792
10.

Serum free and bio-available 25-hydroxyvitamin D correlate better with bone density than serum total 25-hydroxyvitamin D.

Johnsen MS, Grimnes G, Figenschau Y, Torjesen PA, Almås B, Jorde R.

Scand J Clin Lab Invest. 2014 Apr;74(3):177-83. doi: 10.3109/00365513.2013.869701. Epub 2014 Jan 2. Erratum in: Scand J Clin Lab Invest. 2014 Aug;74(5):464.

PMID:
24383929
11.

The phosphodiesterase 8B gene rs4704397 is associated with thyroid function, risk of myocardial infarction, and body height: the Tromsø study.

Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njølstad I, Løchen ML, Figenschau Y, Svartberg J, Hutchinson MS, Kjærgaard M, Jørgensen L, Grimnes G.

Thyroid. 2014 Feb;24(2):215-22. doi: 10.1089/thy.2013.0177. Epub 2013 Nov 13.

PMID:
23941514
12.

Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study.

Jorde R, Schirmer H, Njølstad I, Løchen ML, Bøgeberg Mathiesen E, Kamycheva E, Figenschau Y, Grimnes G.

Eur J Epidemiol. 2013 Jul;28(7):569-78. doi: 10.1007/s10654-013-9822-y. Epub 2013 Jul 17.

PMID:
23860708
13.

Effects of Age and Sex on Estimated Diabetes Prevalence Using Different Diagnostic Criteria: The Tromsø OGTT Study.

Hutchinson MS, Joakimsen RM, Njølstad I, Schirmer H, Figenschau Y, Svartberg J, Jorde R.

Int J Endocrinol. 2013;2013:613475. doi: 10.1155/2013/613475. Epub 2013 Jan 9.

14.

Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial.

Kjærgaard M, Waterloo K, Wang CE, Almås B, Figenschau Y, Hutchinson MS, Svartberg J, Jorde R.

Br J Psychiatry. 2012 Nov;201(5):360-8. doi: 10.1192/bjp.bp.111.104349. Epub 2012 Jul 12.

PMID:
22790678
15.

Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study.

Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njølstad I, Løchen ML, Figenschau Y, Berg JP, Svartberg J, Grimnes G.

PLoS One. 2012;7(5):e37295. doi: 10.1371/journal.pone.0037295. Epub 2012 May 23.

16.

Serum 25-hydroxyvitamin D levels in subjects with reduced glucose tolerance and type 2 diabetes - the Tromsø OGTT-study.

Hutchinson MS, Figenschau Y, Almås B, Njølstad I, Jorde R.

Int J Vitam Nutr Res. 2011 Sep;81(5):317-27. doi: 10.1024/0300-9831/a000079.

PMID:
22419202
17.

Glycated hemoglobin in diagnosis of diabetes mellitus and pre-diabetes; validation by oral glucose tolerance test. The Tromsø OGTT Study.

Hutchinson MS, Joakimsen RM, Njølstad I, Schirmer H, Figenschau Y, Jorde R.

J Endocrinol Invest. 2012 Oct;35(9):835-40. doi: 10.3275/8191. Epub 2011 Dec 16.

PMID:
22186659
18.

Staphylococcus epidermidis polysaccharide intercellular adhesin activates complement.

Fredheim EG, Granslo HN, Flægstad T, Figenschau Y, Rohde H, Sadovskaya I, Mollnes TE, Klingenberg C.

FEMS Immunol Med Microbiol. 2011 Nov;63(2):269-80. doi: 10.1111/j.1574-695X.2011.00854.x.

19.

Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique.

Grimnes G, Figenschau Y, Almås B, Jorde R.

Diabetes. 2011 Nov;60(11):2748-57. doi: 10.2337/db11-0650. Epub 2011 Sep 12.

20.

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.

Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B, Jorde R.

Osteoporos Int. 2012 Jan;23(1):201-11. doi: 10.1007/s00198-011-1752-5. Epub 2011 Sep 10.

PMID:
21909730
21.

Differences in serum levels of CB-153 and p,p'-DDE, and reproductive parameters between men living south and north in Norway.

Haugen TB, Tefre T, Malm G, Jönsson BA, Rylander L, Hagmar L, Bjørsvik C, Henrichsen T, Sæther T, Figenschau Y, Giwercman A.

Reprod Toxicol. 2011 Nov;32(3):261-7. doi: 10.1016/j.reprotox.2011.06.072. Epub 2011 Jun 25.

PMID:
21736938
22.

Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study.

Lilleng H, Abeler K, Johnsen SH, Stensland E, Løseth S, Jorde R, Figenschau Y, Lindal S, Wilsgaard T, Bekkelund SI.

Neuromuscul Disord. 2011 Jul;21(7):494-500. doi: 10.1016/j.nmd.2011.04.007. Epub 2011 May 17.

PMID:
21592795
23.

Serum 25-hydroxyvitamin D levels are inversely associated with glycated haemoglobin (HbA(1c)). The Tromsø Study.

Hutchinson MS, Figenschau Y, Njølstad I, Schirmer H, Jorde R.

Scand J Clin Lab Invest. 2011 Sep;71(5):399-406. doi: 10.3109/00365513.2011.575235. Epub 2011 Apr 26.

PMID:
21517716
24.

Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157).

Berg V, Sveinbjörnsson B, Bendiksen S, Brox J, Meknas K, Figenschau Y.

Arthritis Res Ther. 2010;12(6):R228. doi: 10.1186/ar3215. Epub 2010 Dec 30.

25.

The secretory profiles of cultured human articular chondrocytes and mesenchymal stem cells: implications for autologous cell transplantation strategies.

Polacek M, Bruun JA, Elvenes J, Figenschau Y, Martinez I.

Cell Transplant. 2011;20(9):1381-93. doi: 10.3727/096368910X550215. Epub 2010 Dec 22.

PMID:
21176404
26.

Baseline serum 25-hydroxyvitamin D concentrations in the Tromsø Study 1994-95 and risk of developing type 2 diabetes mellitus during 11 years of follow-up.

Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jenssen T, Njølstad I, Schirmer H, Jorde R.

Diabet Med. 2010 Oct;27(10):1107-15. doi: 10.1111/j.1464-5491.2010.03092.x.

PMID:
20854377
27.

High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile.

Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G.

Eur J Clin Nutr. 2010 Dec;64(12):1457-64. doi: 10.1038/ejcn.2010.176. Epub 2010 Sep 8.

PMID:
20823896
28.

Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed.

Grimnes G, Almaas B, Eggen AE, Emaus N, Figenschau Y, Hopstock LA, Hutchinson MS, Methlie P, Mihailova A, Sneve M, Torjesen P, Wilsgaard T, Jorde R.

Eur J Endocrinol. 2010 Aug;163(2):339-48. doi: 10.1530/EJE-10-0150. Epub 2010 May 17. Erratum in: Eur J Endocrinol. 2010 Dec;163(6):965.

PMID:
20479012
29.

Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study.

Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G.

Am J Epidemiol. 2010 Apr 15;171(8):903-8. doi: 10.1093/aje/kwq005. Epub 2010 Mar 10.

PMID:
20219763
30.

Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study.

Jorde R, Sneve M, Emaus N, Figenschau Y, Grimnes G.

Eur J Nutr. 2010 Oct;49(7):401-7. doi: 10.1007/s00394-010-0098-7. Epub 2010 Mar 4.

PMID:
20204652
31.

Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromsø study.

Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R.

Eur J Endocrinol. 2010 May;162(5):935-42. doi: 10.1530/EJE-09-1041. Epub 2010 Feb 25.

PMID:
20185562
32.

No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year.

Jorde R, Sneve M, Torjesen P, Figenschau Y.

J Intern Med. 2010 May;267(5):462-72. doi: 10.1111/j.1365-2796.2009.02181.x. Epub 2009 Oct 19.

33.

No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects.

Jorde R, Sneve M, Torjesen PA, Figenschau Y, Gøransson LG, Omdal R.

Cytokine. 2010 May;50(2):175-80. doi: 10.1016/j.cyto.2009.12.006. Epub 2010 Feb 1.

PMID:
20122848
34.

Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D.

Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen JB.

Thromb Res. 2010 May;125(5):e210-3. doi: 10.1016/j.thromres.2009.12.011. Epub 2010 Jan 13.

PMID:
20071011
35.

Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension.

Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G.

Hypertension. 2010 Mar;55(3):792-8. doi: 10.1161/HYPERTENSIONAHA.109.143990. Epub 2010 Jan 11.

PMID:
20065152
36.

No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.

Jorde R, Sneve M, Torjesen PA, Figenschau Y, Hansen JB, Grimnes G.

Nutr J. 2010 Jan 7;9:1. doi: 10.1186/1475-2891-9-1.

37.

Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels.

Jorde R, Figenschau Y.

Eur J Nutr. 2009 Sep;48(6):349-54. doi: 10.1007/s00394-009-0020-3. Epub 2009 Apr 16.

PMID:
19370371
38.

Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects.

Sneve M, Figenschau Y, Jorde R.

Eur J Endocrinol. 2008 Dec;159(6):675-84. doi: 10.1530/EJE-08-0339.

PMID:
19056900
39.

The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study.

Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R.

Thyroid. 2008 Nov;18(11):1147-55. doi: 10.1089/thy.2008.0158.

PMID:
18925834
40.

Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial.

Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K.

J Intern Med. 2008 Dec;264(6):599-609. doi: 10.1111/j.1365-2796.2008.02008.x. Epub 2008 Sep 10.

41.

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip.

Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R.

Int J Impot Res. 2008 Jul-Aug;20(4):378-87. doi: 10.1038/ijir.2008.19. Epub 2008 May 15.

PMID:
18480825
42.
43.

Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis.

Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E.

BMC Womens Health. 2008 Jan 14;8:1. doi: 10.1186/1472-6874-8-1.

44.

Thyroid stimulating hormone and left ventricular function.

Iqbal A, Schirmer H, Lunde P, Figenschau Y, Rasmussen K, Jorde R.

J Clin Endocrinol Metab. 2007 Sep;92(9):3504-10. Epub 2007 Jun 12.

PMID:
17566088
45.

Seasonal variation in serum concentrations of reproductive hormones and urinary excretion of 6-sulfatoxymelatonin in men living north and south of the Arctic Circle: a longitudinal study.

Ruhayel Y, Malm G, Haugen TB, Henrichsen T, Bjørsvik C, Grotmol T, Saether T, Malm J, Figenschau Y, Rylander L, Levine RJ, Giwercman A.

Clin Endocrinol (Oxf). 2007 Jul;67(1):85-92. Epub 2007 Jun 4.

PMID:
17547693
46.
47.

Serum levels of vitamin D and haemostatic factors in healthy subjects: the Tromsø study.

Jorde R, Haug E, Figenschau Y, Hansen JB.

Acta Haematol. 2007;117(2):91-7. Epub 2006 Nov 28.

PMID:
17135721
48.

Blood pressure in relation to serum thyrotropin: The Tromsø study.

Iqbal A, Figenschau Y, Jorde R.

J Hum Hypertens. 2006 Dec;20(12):932-6. Epub 2006 Oct 5.

PMID:
17024137
50.

Haemostatic function in subjects with mild subclinical hypothyroidism. The Tromsø study.

Jorde R, Figenschau Y, Hansen JB.

Thromb Haemost. 2006 Apr;95(4):750-1. No abstract available.

PMID:
16601854

Supplemental Content

Loading ...
Support Center